{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:02:52Z","timestamp":1791327772125,"version":"4.3.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40257-026-01031-4","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:59:11Z","timestamp":1778752751000},"page":"887-907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genomics of Primary and Metastatic Cutaneous Melanoma: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"27","author":[{"given":"Manh Duc","family":"Hoang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Oanh","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Tu","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Quang","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9leste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5594-6694","authenticated-orcid":false,"given":"Guilhem","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"1031_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1031_CR2","unstructured":"IARC. Cancer today. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/16-melanoma-of-skin-fact-sheet.pdf. Accessed 27 Aug 2024."},{"key":"1031_CR3","unstructured":"SEER. Melanoma of the skin: cancer stat facts. https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html. Accessed 1 Mar 2025."},{"key":"1031_CR4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1001\/jamadermatol.2023.3256","volume":"159","author":"NM Helvind","year":"2023","unstructured":"Helvind NM, Brinch-M\u00f8ller Weitemeyer M, Chakera AH, Hendel HW, Elleb\u00e6k E, Svane IM, et al. Stage-specific risk of recurrence and death from melanoma in Denmark, 2008-2021: a national observational cohort study of 25\u202f720 patients with stage IA to IV melanoma. JAMA Dermatol. 2023;159:1213\u201322. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3256.","journal-title":"JAMA Dermatol"},{"key":"1031_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40:127\u201337. https:\/\/doi.org\/10.1200\/JCO.21.02229.","journal-title":"J Clin Oncol"},{"key":"1031_CR6","doi-asserted-by":"publisher","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1904059.","DOI":"10.1056\/NEJMoa1904059"},{"key":"1031_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2022.09.004","volume":"176","author":"P Serra-Bellver","year":"2022","unstructured":"Serra-Bellver P, Versluis JM, Oberoi HK, Zhou C, Slattery TD, Khan Y, et al. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. Eur J Cancer. 2022;176:121\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2022.09.004.","journal-title":"Eur J Cancer"},{"key":"1031_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.eururo.2021.12.010","volume":"81","author":"TO Bui","year":"2022","unstructured":"Bui TO, Dao VT, Nguyen VT, Feugeas J-P, Pamoukdjian F, Bousquet G. Genomics of clear-cell renal cell carcinoma: a systematic review and meta-analysis. Eur Urol. 2022;81:349\u201361. https:\/\/doi.org\/10.1016\/j.eururo.2021.12.010.","journal-title":"Eur Urol"},{"key":"1031_CR9","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoff mann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"1031_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12863-015-0211-2\/","volume":"16","author":"ZN Sohani","year":"2015","unstructured":"Sohani ZN, Meyre D, de Souza RJ, Joseph PG, Gandhi M, Dennis BB, et al. Assessing the quality of published genetic association studies in meta-analyses: the quality of genetic studies (Q-Genie) tool. BMC Genet. 2015;16:50. https:\/\/doi.org\/10.1186\/s12863-015-0211-2\/.","journal-title":"BMC Genet"},{"key":"1031_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061728","volume":"15","author":"TT Nguyen","year":"2023","unstructured":"Nguyen TT, Hamdan D, Angeli E, Feugeas J-P, Le QV, Pamoukdjian F, et al. Genomics of breast cancer brain metastases: a meta-analysis and therapeutic implications. Cancers. 2023;15:1728. https:\/\/doi.org\/10.3390\/cancers15061728.","journal-title":"Cancers"},{"key":"1031_CR12","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681\u201396. https:\/\/doi.org\/10.1016\/j.cell.2015.05.044.","journal-title":"Cell"},{"key":"1031_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/genes11111342","volume":"11","author":"M \u015amiech","year":"2020","unstructured":"\u015amiech M, Leszczy\u0144ski P, Kono H, Wardell C, Taniguchi H. Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks. Genes. 2020;11:1342. https:\/\/doi.org\/10.3390\/genes11111342.","journal-title":"Genes"},{"key":"1031_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"PTC Wan","year":"2004","unstructured":"Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855\u201367. https:\/\/doi.org\/10.1016\/S0092-8674(04)00215-6.","journal-title":"Cell"},{"key":"1031_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(15)60898-4.","journal-title":"Lancet"},{"key":"1031_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:603\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(18)30142-6.","journal-title":"Lancet Oncol"},{"key":"1031_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01631-9","volume":"17","author":"X Yang","year":"2024","unstructured":"Yang X, Wu H. RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms. J Hematol Oncol. 2024;17:108. https:\/\/doi.org\/10.1186\/s13045-024-01631-9.","journal-title":"J Hematol Oncol"},{"key":"1031_CR18","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-09-4254","volume":"70","author":"C Milagre","year":"2010","unstructured":"Milagre C, Dhomen N, Geyer FC, Hayward R, Lambros M, Reis-Filho JS, et al. A mouse model of melanoma driven by oncogenic KRAS. Cancer Res. 2010;70:5549\u201357. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4254.","journal-title":"Cancer Res"},{"key":"1031_CR19","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1038\/sj.onc.1210239","volume":"26","author":"T Whitwam","year":"2007","unstructured":"Whitwam T, VanBrocklin MW, Russo ME, Haak PT, Bilgili D, Resau JH, et al. Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene. 2007;26:4563\u201370. https:\/\/doi.org\/10.1038\/sj.onc.1210239.","journal-title":"Oncogene"},{"key":"1031_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.molmed.2011.08.001","volume":"18","author":"Z Ji","year":"2012","unstructured":"Ji Z, Flaherty KT, Tsao H. Targeting the RAS pathway in melanoma. Trends Mol Med. 2012;18:27\u201335. https:\/\/doi.org\/10.1016\/j.molmed.2011.08.001.","journal-title":"Trends Mol Med"},{"key":"1031_CR21","doi-asserted-by":"publisher","first-page":"9483","DOI":"10.1158\/0008-5472.CAN-05-4227","volume":"66","author":"N Dumaz","year":"2006","unstructured":"Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 2006;66:9483\u201391. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4227.","journal-title":"Cancer Res"},{"key":"1031_CR22","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973\u20137. https:\/\/doi.org\/10.1038\/nature09626.","journal-title":"Nature"},{"issue":"4","key":"1031_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","volume":"18","author":"R Dummer","year":"2017","unstructured":"Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(4):435\u201345.","journal-title":"Lancet Oncol"},{"key":"1031_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/labinvest.2016.142","volume":"97","author":"M Kiuru","year":"2017","unstructured":"Kiuru M, Busam KJ. The NF1 gene in tumor syndromes and melanoma. Lab Invest. 2017;97:146\u201357. https:\/\/doi.org\/10.1038\/labinvest.2016.142.","journal-title":"Lab Invest"},{"key":"1031_CR25","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.3390\/cancers15133527","volume":"15","author":"A Panning","year":"2023","unstructured":"Panning A, Samlowski W, Allred G. Lack of influence of non-overlapping mutations in BRAF, NRAS, or NF1 on 12-month best objective response and long-term survival after checkpoint inhibitor-based treatment for metastatic melanoma. Cancers. 2023;15:3527. https:\/\/doi.org\/10.3390\/cancers15133527.","journal-title":"Cancers"},{"key":"1031_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.589929","volume":"11","author":"M Dratwa","year":"2020","unstructured":"Dratwa M, Wysocza\u0144ska B, \u0141acina P, Kubik T, Bogunia-Kubik K. TERT: regulation and roles in cancer formation. Front Immunol. 2020;11:589929. https:\/\/doi.org\/10.3389\/fimmu.2020.589929.","journal-title":"Front Immunol"},{"key":"1031_CR27","doi-asserted-by":"publisher","first-page":"14402","DOI":"10.1073\/pnas.1611106113","volume":"113","author":"Y Li","year":"2016","unstructured":"Li Y, Cheng HS, Chng WJ, Tergaonkar V. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. Proc Natl Acad Sci. 2016;113:14402\u20137. https:\/\/doi.org\/10.1073\/pnas.1611106113.","journal-title":"Proc Natl Acad Sci"},{"key":"1031_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.molcel.2011.02.020","volume":"42","author":"AL Kennedy","year":"2011","unstructured":"Kennedy AL, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS, et al. Activation of the PIK3CA\/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell. 2011;42:36\u201349. https:\/\/doi.org\/10.1016\/j.molcel.2011.02.020.","journal-title":"Mol Cell"},{"key":"1031_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s13577-019-00270-4","volume":"33","author":"D Cio\u0142czyk-Wierzbicka","year":"2020","unstructured":"Cio\u0142czyk-Wierzbicka D, Gil D, Zarzycka M, Laidler P. mTOR inhibitor everolimus reduces invasiveness of melanoma cells. Hum Cell. 2020;33:88\u201397. https:\/\/doi.org\/10.1007\/s13577-019-00270-4.","journal-title":"Hum Cell"},{"key":"1031_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s12079-019-00510-0","volume":"13","author":"D Cio\u0142czyk-Wierzbicka","year":"2019","unstructured":"Cio\u0142czyk-Wierzbicka D, Zarzycka M, Gil D, Laidler P. mTOR inhibitor Everolimus-induced apoptosis in melanoma cells. J Cell Commun Signal. 2019;13:357\u201368. https:\/\/doi.org\/10.1007\/s12079-019-00510-0.","journal-title":"J Cell Commun Signal."},{"key":"1031_CR31","doi-asserted-by":"publisher","first-page":"8043","DOI":"10.1200\/jco.2006.24.18_suppl.8043","volume":"24","author":"RD Rao","year":"2006","unstructured":"Rao RD, Windschitl HE, Allred JB, Lowe VJ, Maples WJ, Gornet MK, et al. Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. J Clin Oncol. 2006;24:8043. https:\/\/doi.org\/10.1200\/jco.2006.24.18_suppl.8043.","journal-title":"J Clin Oncol"},{"key":"1031_CR32","doi-asserted-by":"publisher","unstructured":"Subbiah V, Sen S, Hess KR, Janku F, Hong DS, Khatua S, et al. Phase I study of the BRAF inhibitor vemurafenib in combination with the mammalian target of rapamycin inhibitor everolimus in patients with BRAF-mutated malignancies. JCO Precis Oncol. 2018;2:PO.18.00189. https:\/\/doi.org\/10.1200\/PO.18.00189.","DOI":"10.1200\/PO.18.00189"},{"key":"1031_CR33","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/CMR.0000000000000014","volume":"23","author":"RJ Hauke","year":"2013","unstructured":"Hauke RJ, Infante JR, Rubin MS, Shih KC, Arrowsmith ER, Hainsworth JD. Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium. Melanoma Res. 2013;23:468\u201373. https:\/\/doi.org\/10.1097\/CMR.0000000000000014.","journal-title":"Melanoma Res"},{"key":"1031_CR34","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a014241\/","volume":"4","author":"M Gabay","year":"2014","unstructured":"Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med. 2014;4:a014241. https:\/\/doi.org\/10.1101\/cshperspect.a014241\/.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1031_CR35","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1101\/gad.836800","volume":"14","author":"R Sears","year":"2000","unstructured":"Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate MYC protein stability. Genes Dev. 2000;14:2501\u201314.","journal-title":"Genes Dev"},{"key":"1031_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102154","volume":"94","author":"MJ Duffy","year":"2021","unstructured":"Duffy MJ, O\u2019Grady S, Tang M, Crown J. MYC as a target for cancer treatment. Cancer Treat Rev. 2021;94:102154. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102154.","journal-title":"Cancer Treat Rev"},{"key":"1031_CR37","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.438","volume":"41","author":"TD Prickett","year":"2009","unstructured":"Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet. 2009;41:1127\u201332. https:\/\/doi.org\/10.1038\/ng.438.","journal-title":"Nat Genet"},{"key":"1031_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","volume":"18","author":"A Drilon","year":"2021","unstructured":"Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent cancers: biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021;18:35\u201355. https:\/\/doi.org\/10.1038\/s41571-020-0408-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"1031_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.666145","volume":"11","author":"S-C Ma","year":"2021","unstructured":"Ma S-C, Zhu H-B, Wang J, Zhang Y-P, Guo X-J, Long L-L, et al. De novo mutation in non-tyrosine kinase domain of ROS1 as a potential predictor of immune checkpoint inhibitors in melanoma. Front Oncol. 2021;11:666145. https:\/\/doi.org\/10.3389\/fonc.2021.666145.","journal-title":"Front Oncol"},{"key":"1031_CR40","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, Ou S-HI, Bang Y-J, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963\u201371. https:\/\/doi.org\/10.1056\/NEJMoa1406766.","journal-title":"N Engl J Med"},{"key":"1031_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","volume":"21","author":"A Drilon","year":"2020","unstructured":"Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:261\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(19)30690-4.","journal-title":"Lancet Oncol"},{"key":"1031_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2302299","volume":"390","author":"A Drilon","year":"2024","unstructured":"Drilon A, Camidge DR, Lin JJ, Kim S-W, Solomon BJ, Dziadziuszko R, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390:118\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2302299.","journal-title":"N Engl J Med"},{"key":"1031_CR43","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","volume":"31","author":"FS Hodi","year":"2013","unstructured":"Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31:3182\u201390. https:\/\/doi.org\/10.1200\/JCO.2012.47.7836.","journal-title":"J Clin Oncol"},{"key":"1031_CR44","unstructured":"PMC. ALK inhibitor response in melanomas expressing EML4-ALK fusions and alternate ALK isoforms. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5752582\/. Accessed 11 Apr 2025."},{"key":"1031_CR45","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1167\/iovs.09-4801","volume":"51","author":"MH Abdel-Rahman","year":"2010","unstructured":"Abdel-Rahman MH, Boru G, Massengill J, Salem MM, Davidorf FH. MET oncogene inhibition as a potential target of therapy for uveal melanomas. Invest Ophthalmol Vis Sci. 2010;51:3333\u20139. https:\/\/doi.org\/10.1167\/iovs.09-4801.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1031_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF03401664","volume":"3","author":"WD Foulkes","year":"1997","unstructured":"Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. Mol Med. 1997;3:5\u201320. https:\/\/doi.org\/10.1007\/BF03401664.","journal-title":"Mol Med"},{"key":"1031_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5826\/dpc.0901a03","volume":"9","author":"M Rossi","year":"2019","unstructured":"Rossi M, Pellegrini C, Cardelli L, Ciciarelli V, Di Nardo L, Fargnoli MC. Familial melanoma: diagnostic and management implications. Dermatol Pract Concept. 2019;9:10\u20136. https:\/\/doi.org\/10.5826\/dpc.0901a03.","journal-title":"Dermatol Pract Concept"},{"key":"1031_CR48","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1158\/2159-8290.CD-15-0196","volume":"5","author":"AS McNeal","year":"2015","unstructured":"McNeal AS, Liu K, Nakhate V, Natale CA, Duperret EK, Capell BC, et al. CDKN2B loss promotes progression from benign melanocytic nevus to melanoma. Cancer Discov. 2015;5:1072\u201385. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0196.","journal-title":"Cancer Discov"},{"key":"1031_CR49","doi-asserted-by":"publisher","first-page":"9528","DOI":"10.1200\/JCO.2019.37.15_suppl.9528","volume":"37","author":"L Mao","year":"2019","unstructured":"Mao L, Cao Y, Sheng X, Bai X, Chi Z, Cui C, et al. Palbociclib (P) in advanced acral lentiginous melanoma (ALM) with CDK4 pathway gene aberrations. J Clin Oncol. 2019;37:9528. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.9528.","journal-title":"J Clin Oncol"},{"key":"1031_CR50","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1158\/1078-0432.CCR-20-4050","volume":"27","author":"B Louveau","year":"2021","unstructured":"Louveau B, Resche-Rigon M, Lesimple T, Da Meda L, Pracht M, Baroudjian B, et al. Phase I-II open-label multicenter study of palbociclib + vemurafenib in BRAFV600MUT metastatic melanoma patients: uncovering CHEK2 as a major response mechanism. Clin Cancer Res. 2021;27:3876\u201383. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4050.","journal-title":"Clin Cancer Res"},{"key":"1031_CR51","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41467-024-55316-5","volume":"16","author":"M Gounder","year":"2025","unstructured":"Gounder M, Johnson M, Heist RS, Shapiro GI, Postel-Vinay S, Wilson FH, et al. MAT2A inhibitor AG-270\/S095033 in patients with advanced malignancies: a phase I trial. Nat Commun. 2025;16:423. https:\/\/doi.org\/10.1038\/s41467-024-55316-5.","journal-title":"Nat Commun"},{"key":"1031_CR52","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/B978-0-12-380916-2.00005-X","volume":"94","author":"M Chinnam","year":"2011","unstructured":"Chinnam M, Goodrich DW. RB1, development, and cancer. Curr Top Dev Biol. 2011;94:129\u201369. https:\/\/doi.org\/10.1016\/B978-0-12-380916-2.00005-X.","journal-title":"Curr Top Dev Biol"},{"key":"1031_CR53","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026062","volume":"6","author":"BJ Aubrey","year":"2016","unstructured":"Aubrey BJ, Strasser A, Kelly GL. Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb Perspect Med. 2016;6:a026062. https:\/\/doi.org\/10.1101\/cshperspect.a026062.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1031_CR54","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3390\/life12091339","volume":"12","author":"A Loras","year":"2022","unstructured":"Loras A, Gil-Barrachina M, Marqu\u00e9s-Torrej\u00f3n M\u00c1, Perez-Pastor G, Martinez-Cadenas C. UV-induced somatic mutations driving clonal evolution in healthy skin, nevus, and cutaneous melanoma. Life. 2022;12:1339. https:\/\/doi.org\/10.3390\/life12091339.","journal-title":"Life"},{"key":"1031_CR55","doi-asserted-by":"publisher","first-page":"14025","DOI":"10.1073\/pnas.93.24.14025","volume":"93","author":"AS Jonason","year":"1996","unstructured":"Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA. 1996;93:14025\u20139. https:\/\/doi.org\/10.1073\/pnas.93.24.14025.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1031_CR56","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ebiom.2018.05.019","volume":"32","author":"W Xiao","year":"2018","unstructured":"Xiao W, Du N, Huang T, Guo J, Mo X, Yuan T, et al. TP53 mutation as potential negative predictor for response of anti-CTLA-4 therapy in metastatic melanoma. EBioMedicine. 2018;32:119\u201324. https:\/\/doi.org\/10.1016\/j.ebiom.2018.05.019.","journal-title":"EBioMedicine"},{"key":"1031_CR57","doi-asserted-by":"publisher","first-page":"117693512311772","DOI":"10.1177\/11769351231177267","volume":"22","author":"SU Khan","year":"2023","unstructured":"Khan SU, Ullah Z, Shaukat H, Unab S, Jannat S, Ali W, et al. TP53 and its regulatory genes as prognosis of cutaneous melanoma. Cancer Inform. 2023;22:11769351231177268. https:\/\/doi.org\/10.1177\/11769351231177267.","journal-title":"Cancer Inform."},{"key":"1031_CR58","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1038\/onc.2012.502","volume":"32","author":"S Pandolfi","year":"2013","unstructured":"Pandolfi S, Montagnani V, Penachioni JY, Vinci MC, Olivito B, Borgognoni L, et al. WIP1 phosphatase modulates the Hedgehog signaling by enhancing GLI1 function. Oncogene. 2013;32:4737\u201347. https:\/\/doi.org\/10.1038\/onc.2012.502.","journal-title":"Oncogene"},{"key":"1031_CR59","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41568-022-00443-8","volume":"22","author":"GM Alicea","year":"2022","unstructured":"Alicea GM, Rebecca VW. Un-fair skin: racial disparities in acral melanoma research. Nat Rev Cancer. 2022;22:127\u20138. https:\/\/doi.org\/10.1038\/s41568-022-00443-8.","journal-title":"Nat Rev Cancer"},{"key":"1031_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18988-3","volume":"11","author":"F Newell","year":"2020","unstructured":"Newell F, Wilmott JS, Johansson PA, Nones K, Addala V, Mukhopadhyay P, et al. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun. 2020;11:5259. https:\/\/doi.org\/10.1038\/s41467-020-18988-3.","journal-title":"Nat Commun"},{"key":"1031_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0283159","volume":"18","author":"SB Jacobsen","year":"2023","unstructured":"Jacobsen SB, Tfelt-Hansen J, Smerup MH, Andersen JD, Morling N. Comparison of whole transcriptome sequencing of fresh, frozen, and formalin-fixed, paraffin-embedded cardiac tissue. PLoS ONE. 2023;18:e0283159. https:\/\/doi.org\/10.1371\/journal.pone.0283159.","journal-title":"PLoS ONE"},{"key":"1031_CR62","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.annonc.2022.05.522","volume":"33","author":"E Pleasance","year":"2022","unstructured":"Pleasance E, Bohm A, Williamson LM, Nelson JMT, Shen Y, Bonakdar M, et al. Whole-genome and transcriptome analysis enhances precision cancer treatment options. Ann Oncol. 2022;33:939\u201349. https:\/\/doi.org\/10.1016\/j.annonc.2022.05.522.","journal-title":"Ann Oncol"},{"key":"1031_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00408-z","volume":"12","author":"TO Bui","year":"2023","unstructured":"Bui TO, Angeli E, El Bouchtaoui M, Gapihan G, Dao VT, Paris J, et al. Metastatic clear-cell renal cell carcinoma: a frequent NOTCH1 mutation predictive of response to anti-NOTCH1 CB-103 treatment. Exp Hematol Oncol. 2023;12:46. https:\/\/doi.org\/10.1186\/s40164-023-00408-z.","journal-title":"Exp Hematol Oncol"},{"key":"1031_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216281","volume":"24","author":"T Kerkour","year":"2023","unstructured":"Kerkour T, Zhou C, Hollestein L, Mooyaart A. Genetic concordance in primary cutaneous melanoma and matched metastasis: a systematic review and meta-analysis. Int J Mol Sci. 2023;24:16281. https:\/\/doi.org\/10.3390\/ijms242216281.","journal-title":"Int J Mol Sci"},{"key":"1031_CR65","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/jso.27953","volume":"131","author":"C Druskovich","year":"2025","unstructured":"Druskovich C, Kelley J, Aubrey J, Palladino L, Wright GP. A review of melanoma subtypes: genetic and treatment considerations. J Surg Oncol. 2025;131:356\u201364. https:\/\/doi.org\/10.1002\/jso.27953.","journal-title":"J Surg Oncol"}],"updated-by":[{"DOI":"10.1007\/s40257-026-01068-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01031-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01031-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01031-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:31:57Z","timestamp":1789464717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01031-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1031"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01031-4","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to update in article text In the section 3.3 \u201cGene Mutation Profile of Primary Cutaneous Melanoma\u201d.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-026-01068-5","URL":"https:\/\/doi.org\/10.1007\/s40257-026-01068-5","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Manh Duc Hoang, Thi Oanh Bui, Van Tu Dao, Van Quang Le, C\u00e9leste Lebb\u00e9, and Guilhem Bousquet have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data used in this meta-analysis were obtained from published studies. No new datasets were generated. Data supporting the findings of this study are available on request from the corresponding author.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GB, MDH, and TOB conceived the study and developed the research strategy. MDH and TOB conducted the literature search and performed the data extraction and analysis. MDH drafted the manuscript. VTD, VQL, CL, and GB provided critical input during the research process and contributed to the writing of specific sections. GB reviewed and validated the final version of the manuscript. All authors read and approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}